1 – 23 of 23
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Recombinant activated factor VII: 30 years of research and innovation.
(
- Contribution to journal › Scientific review
- 2014
-
Mark
Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?
(
- Contribution to journal › Scientific review
- 2012
-
Mark
Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa.
(
- Contribution to journal › Article
-
Mark
Influence of endothelial cell protein C receptor on plasma clearance of factor VIIa.
(
- Contribution to journal › Letter
-
Mark
Factor VIIa binding to endothelial cell protein C receptor: Differences between mouse and human systems
(
- Contribution to journal › Article
- 2011
-
Mark
Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following IV administration in haemophilia patients.
(
- Contribution to journal › Article
- 2010
-
Mark
Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)
(
- Contribution to journal › Article
-
Mark
rFVIIa transported from the blood stream into tissues is functionally active
(
- Contribution to journal › Letter
-
Mark
History of rFVIIa therapy.
(
- Contribution to journal › Article
- 2009
-
Mark
Fibrin gel structure obtained with a FVIIa analogue with enhanced FX-activating potential in haemophilia
(
- Contribution to journal › Letter
- 2008
-
Mark
FactorVIIa and its potential therapeutic use in bleeding-associated pathologies
(
- Contribution to journal › Article
-
Mark
Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats
(
- Contribution to journal › Article
- 2006
-
Mark
Potential role of rFVIIa in prophylaxis in severe haemophilia patients with inhibitors.
(
- Contribution to journal › Article
- 2005
-
Mark
The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia
(
- Contribution to journal › Article
- 2003
-
Mark
The role of recombinant factor VIIa(FVIIa) in fibrin structure in the absence of FVIII/FIX
(
- Contribution to journal › Article
- 2001
-
Mark
Anti- and procoagulant activities in factor VII-deficient subjects
(
- Contribution to journal › Article
- 2000
-
Mark
Correlation between different intensities of anti-vitamin K treatment and coagulation parameters
(
- Contribution to journal › Article
- 1994
-
Mark
Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis : A comparison with low molecular weight heparin
(
- Contribution to journal › Article
- 1993
-
Mark
Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis
(
- Contribution to journal › Article
- 1990
-
Mark
Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats
(
- Contribution to journal › Article
- 1989
-
Mark
Influence of a low molecular weight heparin on the inhibition of factor Xa and thrombin in hip surgery
(
- Contribution to journal › Article
- 1987
-
Mark
Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers
(
- Contribution to journal › Article
- 1986
-
Mark
Heparin-induced osteoporosis in rats
(
- Contribution to journal › Article